bit.bio's CEO, our cell programming approach and our products prominently covered in synthetic biology article.
04.03.2024bit.bio's CEO, our cell programming approach and our products prominently covered in synthetic biology article.
bit.bio's CEO, our cell programming approach and our products prominently covered in synthetic biology article.
04.03.2024bit.bio's CEO, our cell programming approach and our products prominently covered in synthetic biology article.
Ginkgo Technology Network brings together over 25 partners across an array of capabilities including AI, genetic medicines, biolog...
28.02.2024Editor-in-Chief Carlos-Filipe Pereira interviews our CEO for the Reprogramming Stars series in the journal Cellular Reprogramming.
26.02.2024Award-winning journalist Daniel Levine and bit.bio CEO Mark Kotter discuss industrialised cell programming and its use in research...
23.02.2024Host Matt Pillar and bit.bio CEO Mark Kotter discuss the concept of programmable biology and how it's fuelling a new breed of biot...
19.02.2024Team will present posters including 2 on ioCRISPR-Ready Cells & host an expert panel discussion on the important role of functiona...
30.01.2024Discover how a collaboration delivered bit.bio's ioGlutamatergic Neurons onto the stage at the Royal Institution to appear in the ...
27.12.2023Product will provide robust, standardised tool for study and screening of potential treatments for motor neuron diseases.
06.12.2023Minister Griffith cut the ribbon to officially open bit.bio’s manufacturing and automation labs for the consistent and scalable pr...
05.12.2023